Who are Iteriontherapeutics's investors?

Iteriontherapeutics's investors include Green Park & Golf Ventures, Lumira Ventures, Portal Innovations.

Iteriontherapeutics

Founded 2015 · 15 employees on LinkedIn · 3 known investors

Iterion Therapeutics is a clinical-stage biopharmaceutical company developing cancer therapies targeting the Wnt/β-catenin pathway. Its lead candidate is in clinical trials for advanced hepatocellular carcinoma and other Wnt-driven tumors such as colorectal cancer.

Biotech Healthtech

Founders & leadership

Rahul ArasChief Executive Officer

Ovid TrifaninChief Medical Officer

Steve HorriganinChief Scientific Officer

Investors · 3

Green Park & Golf VenturesDallas · $500K – $2M

Lumira VenturesToronto · $1M – $10M

Portal InnovationsChicago

Competitors · 1

by search overlap

Bioworld22 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Iteriontherapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Iteriontherapeutics do?: Iterion Therapeutics is a clinical-stage biopharmaceutical company developing cancer therapies targeting the Wnt/β-catenin pathway. Its lead candidate is in clinical trials for advanced hepatocellular carcinoma and other Wnt-driven tumors such as colorectal cancer.
Who are Iteriontherapeutics's investors?: Iteriontherapeutics's investors include Green Park & Golf Ventures, Lumira Ventures, Portal Innovations.